$3.00 +0.04 (%) Agenus Inc - NASDAQ

Nov. 26, 2014 | 04:00 PM

Partner Headlines

  1. Agenus Inc - A Potential New Play On Ebola

    Benzinga | Oct. 13, 2014 | 13:01PM EST
  2. Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine

    GuruFocus | Jul. 25, 2014 | 11:07AM EST
  3. Morning Market Movers

    Benzinga | Jul. 1, 2014 | 09:35AM EST
  4. US Stock Futures Gain Ahead Of Manufacturing PMI, Auto Sales

    Benzinga | Jul. 1, 2014 | 07:35AM EST
  5. UPDATE: Agenus Announces Positive Phase 2 Results

    Benzinga | Jul. 1, 2014 | 07:03AM EST
  6. Morning Market Movers

    Benzinga | Jun. 26, 2014 | 09:37AM EST
  7. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 26, 2014 | 08:15AM EST
  8. UPDATE: Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation

    Benzinga | Jun. 26, 2014 | 07:01AM EST
  9. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  10. Morning Market Losers

    Benzinga | Apr. 2, 2014 | 09:55AM EST
  11. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness | Mar. 20, 2014 | 09:59AM EST
  12. Morning Market Losers

    Benzinga | Mar. 20, 2014 | 09:46AM EST
  13. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga | Mar. 20, 2014 | 07:25AM EST
  14. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does Not Meet First or Second Primary Endpoint

    Benzinga | Mar. 20, 2014 | 06:12AM EST
  15. UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody Acquisition

    Benzinga | Feb. 24, 2014 | 07:55AM EST
  16. Agenus Announces Public Offering of Common Stock

    Benzinga | Feb. 4, 2014 | 17:05PM EST
  17. Agenus Names Robert B. Stein as Chief Scientific Officer

    Benzinga | Jan. 13, 2014 | 07:20AM EST
  18. Agenus to Acquire Privately Held 4-Antibody AG for $10M in Stock

    Benzinga | Jan. 13, 2014 | 07:11AM EST
  19. Agenus Announces Positive Phase 2 Brain Cancer Vaccine Results Published in Neuro-Oncology

    Benzinga | Dec. 16, 2013 | 07:04AM EST
  20. Agenus' HerpV Therapeutic Genital Herpes Vaccine Meets Primary Endpoint in Randomized Phase 2 Trial

    Benzinga | Nov. 7, 2013 | 07:05AM EST
  21. Morning Market Movers

    Benzinga | Oct. 8, 2013 | 09:53AM EST
  22. Agenus Enters into Non-Exclusive License Agreement with VaxLogic for QS-21 Stimulon1 Adjuvant

    Benzinga | Sep. 26, 2013 | 07:03AM EST
  23. Morning Market Movers

    Benzinga | Sep. 17, 2013 | 09:53AM EST
  24. Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine

    Benzinga | Sep. 17, 2013 | 07:04AM EST
  25. Morning Market Losers

    Benzinga | Sep. 5, 2013 | 10:03AM EST
  26. GlaxoSmithKline's Phase 3 Malaria Vaccine Study Meets Primary Endpoint

    Benzinga | Nov. 8, 2012 | 23:07PM EST
  27. Antigenics Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 03:36AM EST
  28. Agenus Initiates Phase 2 Study of Genital Herpes Vaccine

    Benzinga | Oct. 23, 2012 | 01:18AM EST
  29. Aeras Signs Agreement with GSK to Jointly Develop TB Vaccine

    Benzinga | Oct. 10, 2012 | 00:18AM EST
  30. Antigenics Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 07:20AM EST
  31. 5 Speculative Biotech Stocks to Consider Buying Now

    GuruFocus | Jan. 24, 2012 | 11:09AM EST
  32. Antigenics Inc. (AGEN) CFO Shalini Sharp sells 4,564 Shares

    GuruFocus | Dec. 29, 2011 | 10:17AM EST
  33. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 29, 2011 | 03:25AM EST
  34. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 20, 2011 | 00:13AM EST
Trading Center